AVI-4658 (Eteplirsen)

DRUG2 trials

Sponsors

Sarepta Therapeutics, Inc.

Conditions

Duchenne Muscular DystrophyDuchenne Muscular Dystrophy (DMD)

Phase 2

Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients

CompletedNCT01396239

Sarepta Therapeutics, Inc.Duchenne Muscular Dystrophy

Start: 2011-07-31End: 2012-06-30Updated: 2020-03-30

Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy

CompletedNCT01540409

Sarepta Therapeutics, Inc.Duchenne Muscular Dystrophy (DMD)

Start: 2012-02-27End: 2017-08-16Updated: 2020-03-30

Related Papers

A Movement Monitor Based on Magneto-Inertial Sensors for Non-Ambulant Patients with Duchenne Muscular Dystrophy: A Pilot Study in Controlled Environment

PLoS ONE2016-06-0751 citations